Sep 12, 2022 / 12:10PM GMT
Operator
Everyone, and thank you for joining us for this session of the Morgan Stanley Healthcare Conference. My name is Thibault. I am part of the Pharmaceutical Equity Research team based in London. So before we start, I need to refer to important disclosures. Please see the Morgan Stanley research as website at www.morganstanley.com/research disclosures. If you have any questions, please reach out to your Morgan Services representative. So for this session, I'm delighted to have with me Mark Crossley, CEO of Indivior. Mark, thank you very much for joining us today. So we will shortly do a Q&A, and I will invest -- I will invite investors in the room to ask questions if you wish. But before that, Mark, would you start -- would you like to start with some informatory comments, maybe another view on the current situation and the outlook for Indivior.
Mark Crossley - Indivior PLC - CEO & Executive Director
Sure. Just a brief intro for those that aren't as familiar with Indivior. Indivior
Indivior PLC at Morgan Stanley Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot